prikaz prve stranice dokumenta Pharmacogenetics and the treatment of epilepsy: what do we know?
  Download
PDF 811.62 KB
Scientific paper - Original scientific paper
Pharmacogenetics and the treatment of epilepsy: what do we know?
Pharmacogenomics, 20 (2019), 15; 1093-1101. https://doi.org/10.2217/pgs-2019-0085
Božina, Nada; Sporiš, Ivana Šušak; Božina, Tamara; Klarica-Domjanović, Iva; Tvrdeić, Ante; Sporiš, Davor

Cite this document

Božina, N., Sporiš, I. Š., Božina, T., Klarica Domjanović, I., Tvrdeić, A. & Sporiš, D. (2019). Pharmacogenetics and the treatment of epilepsy: what do we know?. Pharmacogenomics, 20. (15), 1093-1101. doi: 10.2217/pgs-2019-0085

Božina, Nada, et al. "Pharmacogenetics and the treatment of epilepsy: what do we know?." Pharmacogenomics, vol. 20, no. 15, 2019, pp. 1093-1101. https://doi.org/10.2217/pgs-2019-0085

Božina, Nada, Ivana Šušak Sporiš, Tamara Božina, Iva Klarica Domjanović, Ante Tvrdeić and Davor Sporiš. "Pharmacogenetics and the treatment of epilepsy: what do we know?." Pharmacogenomics 20, no. 15 (2019): 1093-1101. https://doi.org/10.2217/pgs-2019-0085

Božina, N., et al. (2019) 'Pharmacogenetics and the treatment of epilepsy: what do we know?', Pharmacogenomics, 20(15), pp. 1093-1101. doi: 10.2217/pgs-2019-0085

Božina N, Sporiš IŠ, Božina T, Klarica Domjanović I, Tvrdeić A, Sporiš D. Pharmacogenetics and the treatment of epilepsy: what do we know?. Pharmacogenomics [Internet]. 2019 October [cited 2024 April 18];20(15):1093-1101. doi: 10.2217/pgs-2019-0085

N. Božina, I. Š. Sporiš, T. Božina, I. Klarica Domjanović, A. Tvrdeić and D. Sporiš, "Pharmacogenetics and the treatment of epilepsy: what do we know?", Pharmacogenomics, vol. 20, no. 15, pp. 1093-1101, October 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:856260. [Accessed: 18 April 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Pharmacogenetics and the treatment of epilepsy: what do we know?
AuthorNada Božina
AuthorIvana Šušak Sporiš
AuthorTamara Božina
AuthorIva Klarica-Domjanović
AuthorAnte Tvrdeić
AuthorDavor Sporiš
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Pharmacology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Pharmacology
Abstract (english)
Seizure control with antiepileptic drugs (AEDs) as well as susceptibility to adverse drug reactions varies among individuals with epilepsy. This interindividual variability is partly determined by genetic factors. However, genetic testing to predict the efficacy and toxicity of AEDs is limited and genetic variability is, as yet, largely unexplainable. Accordingly, genetic testing can only be advised in a very limited number of cases in clinical routine. Currently, by applying different methodologies, many trials have been undertaken to evaluate cost benefits of preventive pharmacogenetic analysis for patients. There is significant progress in sequencing technologies, and focus is on next-generation sequencing-based methods, like exome and genome sequencing. In this review, an overview of the current scientific knowledge considering the pharmacogenetics of AEDs is given.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titlePharmacogenomics
Numberingvol. 20, no. 15, pp. 1093-1101
p-ISSN1462-2416
e-ISSN1744-8042
DOIhttps://doi.org/10.2217/pgs-2019-0085
URN:NBNurn:nbn:hr:105:856260
Publication2019-10
Document URLhttps://www.futuremedicine.com/doi/10.2217/pgs-2019-0085
Type of resourceText
Access conditionsOpen access
Embargo expiration date: 2022-01-20
Terms of useLicence In copyright icon
Created on2021-01-11 10:16:22